Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Sep 19, 2019 (7 years ago)

Dextroamphetamine Sacharate

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Superpotent Drug: Amphetamine Mixed Salts 20mg have been found to be out of specification for weight and thickness.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Dextroamphetamine Sacharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Mixed Salts of a single Entity Amphetamine Product), 20mg, 100-count bottle, RX Only, Distributed by: Aurobindo Pharma USA Inc., Dayton, NJ 08810, NDC 13107-073-01

Affected NDC 13107-0073-01

Compare with the code on your package — it is the most precise check available.

Drug: Dextroamphetamine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate
NDC 13107-0073
DEXTROAMPHETAMINE SACCHARATE 5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 5 mg/1; DEXTROAMPHETAMINE SULFATE 5 mg/1; AMPHETAMINE SULFATE 5 mg/1 Tablet
Oral
Aurolife Pharma, LLC Rx · CII
Recalling firm
Aurobindo Pharma USA Inc.
NDC code
13107-073-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0143-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Dextroamphetamine recalls

See all
Class II · Moderate risk

Dextroamphetamine Saccharate

Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.

Ongoing Labeling / mix-up Lannett Company Inc. D-0660-2026

Other recalls by Aurobindo Pharma USA Inc.

All 2019 recalls
Class II · Moderate risk

Acetaminophen Tablets

cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets).

Ongoing Failed specification Aurobindo Pharma USA Inc NDC 72288-405-10 D-0471-2025
Class II · Moderate risk

Nebivolol Tablets

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc D-0149-2025
Class II · Moderate risk

Cinacalcet Tablets

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc NDC 65862-833-30 D-0079-2025